BRISBANE, Calif.--(BUSINESS WIRE)--May 9, 2017--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing CODIT™ (Characterized Oral Desensitization
ImmunoTherapy) treatments for life-threatening food
allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will
present a company overview at the Bank of America Merrill Lynch
Healthcare Conference in Las Vegas on Tuesday, May 16, at 1:00 p.m.
The live webcast of the presentation will be accessible on the Events
page under the Investor Relations section of the Aimmune website at www.aimmune.com.
The replay of the webcast will be available for at least 30 days
following the webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy
(CODIT™) approach is intended to achieve meaningful levels of protection
by desensitizing patients with defined, precise amounts of key
allergens. Aimmune’s first investigational product using CODIT™, AR101
for the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age and is currently being evaluated in Phase 3 clinical
trials in ages 4-55. AR101 is a characterized, regulated, oral
biological drug product containing the protein profile found in peanuts.
For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170509005531/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,